Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate iBio, Inc. before investing.

In this article, we go over a few key elements for understanding iBio, Inc.’s stock price such as:

• iBio, Inc.’s current stock price and volume
• Why iBio, Inc.’s stock price changed recently
• Upgrades and downgrades for IBIO from analysts
• IBIO’s stock price momentum as measured by its relative strength

About iBio, Inc. (IBIO)

Before we jump into iBio, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company’s technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2–expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Want to learn more about iBio, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about iBio, Inc..

iBio, Inc.’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, iBio, Inc.’s stock price was $1.310.

iBio, Inc. is up 0.77% from its previous closing price of $1.300.

During the last market session, iBio, Inc.’s stock traded between $1.280 and $1.330. Currently, there are approximately 145.36 million shares outstanding for iBio, Inc..

iBio, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

iBio, Inc. Stock Price History

iBio, Inc.’s (IBIO) price is currently up 3.15% so far this month.

During the month of September, iBio, Inc.’s stock price has reached a high of $1.350 and a low of $1.210.

Over the last year, iBio, Inc. has hit prices as high as $3.820 and as low as $0.771. Year to date, iBio, Inc.’s stock is down 32.12%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused iBio, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there were analysts who downgraded iBio, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate iBio, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on iBio, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about iBio, Inc. (IBIO) by visiting AAII Stock Evaluator.

Relative Price Strength of iBio, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, iBio, Inc. has a weighted four-quarter relative price strength of 10.19%, which translates to a Momentum Score of 82 and is considered to be Very Strong.

Want to learn more about how iBio, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

iBio, Inc. Stock Price: Bottom Line

As of September 4, 2026, iBio, Inc.’s stock price is $1.310, which is up 0.77% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like iBio, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.